Cliff Asness's ARWR Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 167,210 shares of Arrowhead Pharmaceuticals, Inc. (ARWR) worth $10.33 M, representing 0.00% of the portfolio. First purchased in 2016-Q4, this long-term strategic position has been held for 27 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in ARWR, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2020, adding 311,829 shares. Largest reduction occurred in Q3 2020, reducing 214,904 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Arrowhead Pharmaceuticals (ARWR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Arrowhead Pharmaceuticals (ARWR) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +19,857 | Add 13.48% | 167,210 | $61.76 |
| Q4 2025 | +4,528 | Add 3.17% | 147,353 | $66.39 |
| Q3 2025 | -9,526 | Reduce 6.25% | 142,825 | $34.49 |
| Q2 2025 | +111,845 | Add 276.12% | 152,351 | $15.80 |
| Q1 2025 | +40,506 | New Buy | 40,506 | $12.68 |
| Q1 2023 | -6,024 | Sold Out | 0 | $0.00 |
| Q4 2022 | -16,928 | Reduce 73.75% | 6,024 | $39.99 |
| Q3 2022 | +3,412 | Add 17.46% | 22,952 | $33.07 |
| Q2 2022 | -97,058 | Reduce 83.24% | 19,540 | $33.37 |
| Q1 2022 | +68,268 | Add 141.25% | 116,598 | $45.99 |
| Q4 2021 | -9,263 | Reduce 16.08% | 48,330 | $66.29 |
| Q3 2021 | +12,427 | Add 27.51% | 57,593 | $61.90 |
| Q2 2021 | +19,212 | Add 74.02% | 45,166 | $82.03 |
| Q1 2021 | -10,144 | Reduce 28.10% | 25,954 | $66.31 |
| Q4 2020 | -35,328 | Reduce 49.46% | 36,098 | $76.15 |
| Q3 2020 | -214,904 | Reduce 75.05% | 71,426 | $43.07 |
| Q2 2020 | -151,695 | Reduce 34.63% | 286,330 | $42.27 |
| Q1 2020 | +311,829 | Add 247.10% | 438,025 | $28.77 |
| Q4 2019 | -39,881 | Reduce 24.01% | 126,196 | $63.43 |
| Q3 2019 | -185,633 | Reduce 52.78% | 166,077 | $28.18 |
| Q2 2019 | +157,759 | Add 81.34% | 351,710 | $26.50 |
| Q1 2019 | +77,938 | Add 67.18% | 193,951 | $18.35 |
| Q4 2018 | +5,934 | Add 5.39% | 116,013 | $12.42 |
| Q3 2018 | -18,342 | Reduce 14.28% | 110,079 | $19.17 |
| Q2 2018 | +128,421 | New Buy | 128,421 | $13.60 |
| Q1 2017 | -30,232 | Sold Out | 0 | $0.00 |
| Q4 2016 | +30,232 | New Buy | 30,232 | $1.55 |
Cliff Asness's Arrowhead Pharmaceuticals Investment FAQs
Cliff Asness first purchased Arrowhead Pharmaceuticals, Inc. (ARWR) in Q4 2016, acquiring 30,232 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Arrowhead Pharmaceuticals, Inc. (ARWR) for 27 quarters since Q4 2016.
Cliff Asness's largest addition to Arrowhead Pharmaceuticals, Inc. (ARWR) was in Q1 2020, adding 438,025 shares worth $12.6 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 167,210 shares of Arrowhead Pharmaceuticals, Inc. (ARWR), valued at approximately $10.33 M.
As of the Q1 2026 filing, Arrowhead Pharmaceuticals, Inc. (ARWR) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Arrowhead Pharmaceuticals, Inc. (ARWR) was 438,025 shares, as reported at the end of Q1 2020.